Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

被引：0

作者：

Pellegrini, Cinzia ^{[1
]}

Rigacci, Luigi ^{[2
]}

Patti, Caterina ^{[3
]}

Gini, Guido ^{[4
]}

Mannina, Donato ^{[5
]}

Tani, Monica ^{[6
]}

Rusconi, Chiara ^{[7
]}

Romano, Alessandra ^{[8
]}

Vanazzi, Anna ^{[9
]}

Botto, Barbara ^{[10
]}

Carlo-Stella, Carmelo ^{[11
]}

Hohaus, Stefan ^{[12
]}

Rigolin, Gian Matteo ^{[13
]}

Musto, Pellegrino ^{[14
]}

Mazza, Patrizio ^{[15
]}

Molica, Stefano

Corradini, Paolo ^{[16
]}

Fama, Angelo ^{[17
]}

Gaudio, Francesco ^{[18
]}

Merli, Michele ^{[19
]}

Gravetti, Angela ^{[20
]}

Gritti, Giuseppe ^{[21
]}

Arcari, Annalisa ^{[22
]}

Tosi, Patrizia ^{[23
]}

Liberati, Anna Marina ^{[24
]}

Pinto, Antonello ^{[25
]}

Pavone, Vincenzo ^{[26
]}

Gherlinzoni, Filippo ^{[27
]}

Naso, Virginia ^{[28
]}

Volpetti, Stefano ^{[29
]}

Visentin, Andrea ^{[30
]}

Goldaniga, Maria Cecilia ^{[31
]}

Bonfichi, Maurizio ^{[32
]}

De Renzo, Amalia ^{[33
]}

Schiavotto, Corrado ^{[34
]}

Spina, Michele ^{[35
]}

Storti, Sergio ^{[36
]}

Carella, Angelo Michele ^{[37
]}

Argnani, Lisa ^{[1
]}

Zinzani, Pier Luigi ^{[1
]}

机构：

[1] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[2] Univ & Hosp Careggi, Dept Hematol, Florence, Italy

[3] Dept Hematol, Azienda Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy

[4] Ospedali Riuniti Ancona, Dept Hematol, Ancona, Italy

[5] Osped Papardo, Hematol Unit, Messina, Italy

[6] Santa Maria Croci Hosp, Hematol Unit, Ravenna, Santa Maria, RS, Italy

[7] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy

[8] AOU, Div Haematol, Catania, Italy

[9] European Inst Oncol, Milan, Italy

[10] Azienda Ospedaliera Univ Citta Salute Scienza, SC Ematologia, Turin, Italy

[11] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Oncol & Hematol, Rozzano, Italy

[12] Cathol Univ, Inst Hematol, Rome, Italy

[13] Univ Ferrara, Hematol Sect, Azienda Ospedaliero Univ S Anna, Ferrara, Italy

[14] CROB Rionero Vulture, Rome, Italy

[15] Osped Moscati Dept Hematol Oncol, Taranto, Italy

[16] Fondazione IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy

[17] Ist Ricovero Cura Carattere Scientifico, Hematol Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

[18] Policlinico Bari, Hematol Unit, Bari, Italy

[19] Fondazione Macchi, Hematol, Osped Circolo, Varese, Italy

[20] Cardarelli Hosp, Div Hematol, Stem Cell Transplantat Unit, Naples, Italy

[21] Hosp Papa Giovanni XXIII, Dept Hematol, Bergamo, Italy

[22] Guglielmo da Saliceto Hosp, Div Hematol, Piacenza, Italy

[23] Infermi Hosp Rimini, Hematol Unit, Rimini, Italy

[24] Osped Perugia, Hematol, Perugia, Italy

[25] IRCCS, Natl Canc Inst, Hematol Oncol & Stem Cell Transplantat Unit, Fondazione Pascale, Naples, Italy

[26] Osped G Panico, Div Hematol, Tricase, Lecce, Italy

[27] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[28] SantAndrea Hosp Sapienza, Rome, Italy

[29] DISM, Azienda Sanitaria Univ Integrata, Dept Hematol, Udine, Italy

[30] Univ Padua, Dept Med, Hematol & Clin Immunol Unit, Padua, Italy

[31] Fondazione Ca Granda IRCCS Osped Maggiore Policli, OncoHematol Unit, Milan, Italy

[32] IRCCS Policlinico San Matteo, Hematol, Pavia, Italy

[33] AOU Federico II Napoli, Hematol, Naples, Italy

[34] San Bortolo Hosp, Hematol, Vicenza, Italy

[35] Natl Canc Inst, Div Med Oncol, Aviano, Italy

[36] Univ Cattolica Sacro Cuore Campobasso, Hematol, Campobasso, Italy

[37] IRCCS San Martino IST, Div Hematol 1, Genoa, Italy

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.3007.3007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3007

引用

页数：5

共 50 条

[21] LONG-TERM RESPONDERS AFTER BRENTUXIMAB VEDOTIN: EXPERIENCE ON 57 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN AND ANAPLASTIC LARGE CELL LYMPHOMA
Gandolfi, L.
Celli, M.
Pellegrini, C.
Casadei, B.
Morigi, A.
Stefoni, V.
Broccoli, A.
Quirini, F.
Tonialini, L.
Argnani, L.
Cavo, M.
Zinzani, P. L.
HAEMATOLOGICA, 2015, 100 : 3 - 3
[22] THE ARROVEN STUDY (MA25101): POST-AUTHORISATION OBSERVATIONAL SAFETY STUDY OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA
Linton, K.
Ayto, R.
d'Amore, F.
Moestl, M.
Chau, I.
Paneesha, S.
Kinley, J.
Huebner, D.
Porter, J.
Exter, B.
Wang, B.
Tymoszczuk, J.
Arumainathan, A.
HAEMATOLOGICA, 2015, 100 : 455 - 455
[23] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
A. Salihoglu
T. Elverdi
I. Karadogan
S. Paydas
E. Ozdemir
G. Erdem
N. Karadurmus
G. Akyol
L. Kaynar
ZA Yegin
G. Sucak
V. Ozkocaman
P. Topcuoglu
M. Ozcan
E. Birtas
H. Goker
Z. Baslar
B. Ferhanoglu
Annals of Hematology, 2015, 94 : 415 - 420
[24] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
Ferhanoglu, B.
Salihoglu, A.
Elverdi, T.
Karadogan, I.
Ozdemir, E.
Erdem, G.
Karadurmus, N.
Akyol, G.
Kaynar, L.
Yegin, A.
Sucak, G.
Ozkocaman, V.
Topcuoglu, P.
Ozcan, M.
Birtas, E.
Goker, H.
Baslar, Z.
Paydas, S.
HAEMATOLOGICA, 2014, 99 : 675 - 676
[25] Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real-life study
Massano, Davide
Carraro, Elisa
Mussolin, Lara
Buffardi, Salvatore
Barat, Veronica
Zama, Daniele
Muggeo, Paola
Vendemini, Francesca
Sau, Antonella
Moleti, Maria Luisa
Verzegnassi, Federico
D'Amico, Salvatore
Casini, Tommaso
Garaventa, Alberto
Schiavello, Elisabetta
Cellini, Monica
Vinti, Luciana
Farruggia, Piero
Perruccio, Katia
Cesaro, Simone
De Santis, Raffaela
Marinoni, Maddalena
D'Alba, Irene
Mura, Rosa Maria
Burnelli, Roberta
Mascarin, Maurizio
Pillon, Marta
PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
[26] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Ishizawa, Kenichi
Yanai, Tomoko
ADVANCES IN THERAPY, 2019, 36 (10) : 2679 - 2696
[27] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Kenichi Ishizawa
Tomoko Yanai
Advances in Therapy, 2019, 36 : 2679 - 2696
[28] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
Fukuhara, Noriko
Yamamoto, Go
Tsujimura, Hideki
Chou, Takaaki
Shibayama, Hirohiko
Yanai, Tomoko
Shibuya, Kazunori
Izutsu, Koji
LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
[29] Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Shustov, Andrei R.
Advani, Ranjana
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramachandren, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Yang, Yin
Sievers, Eric L.
Kennedy, Dana A.
Pro, Barbara
BLOOD, 2010, 116 (21) : 423 - 424
[30] Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin
Sasapu, Appalanaidu
Dunn, Andrew L. J.
Gardner, Jerad
Wong, Henry K.
BMJ CASE REPORTS, 2021, 14 (07)

← 1 2 3 4 5 →